<DOC>
	<DOCNO>NCT01863108</DOCNO>
	<brief_summary>The primary objective study evaluate safety tolerability multiple sub-cutaneous injection GeniusVac-Mel4 , dendritic cell-based cancer vaccine , patient melanoma . The secondary objective determine immune response clinical efficacy injection patient melanoma .</brief_summary>
	<brief_title>Safety Study Dendritic Cell-based Cancer Vaccine Melanoma</brief_title>
	<detailed_description>GeniusVac-Mel4 drug product compose irradiated allogeneic plasmacytoid dendritic cell ( PDC ) line load 4 melanoma peptide derive Melan-A , gp100 , Tyrosinase Mage-A3 . This cell line HLA-A*02:01 , phenotype find 40 % European population . This approach exploit PDC line high capacity boost anti-tumor cytotoxic response melanoma antigens HLA-A*02:01 melanoma patient . In preclinical study , strong proof concept bring . Indeed , GeniusVac-Mel4 capacity induce high number cytotoxic antitumor T-cells show melanoma model , vivo humanize mouse ex vivo patient ' PBMC ( peripheral blood mononuclear cell ) ( Aspord et al 2010 2012 ) . It plan include patient three dose-escalating group ( 4 , 20 , 60 million GeniusVac-Mel4 cell ) . At least , 3 patient recruit dose group trial .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<criteria>Patients histologically confirm metastatic melanoma ( stage IIIC stage IV AJCC 2009 classification surgically resectable . Patients respond least one line systemic treatment Male female ( βHCG negative test ) Patients HLAA*0201 Age &gt; 18 year Blood parameter ( Hemoglobin ≥ 10g/dl , Leucocytes ≥ 4000/μl , Lymphocytes ≥ 1000/μl , Platelets ≥100.000/μl , creatinin ≤ 2.0mg/dl , bilirubin ≤ 2.0mg/dl , ASAT ALAT ≤ 2.5 fold upper normal level ) OMS performance score &lt; 3 Informed write consent . Positive serology HCV , HTLV , HIV , active hepatitis Protected person accord French regulation article L11215 L11218 ( Public Health Code ) Nonpregnant woman without effective contraception Any serious acute chronic illness , example : active infection , coagulation disorder . Presence second cancer 5 year precede inclusion study exception situ cervical carcinoma cutaneous carcinoma melanoma . Intercurrent disease require corticosteroid . Any active autoimmune disease include insulin dependent diabetes mellitus . Vitiligo autoimmune thyroid disease criterion exclusion . Autoimmune eye disease . Evidence immunosuppression reason Primary ocular melanoma Chemotherapy , immunotherapy radiotherapy 4 week precede inclusion ( 6 week case nitrosourea mitomycin C ) . Treatment drug development within 4 week . Cerebral metastasis metastasis exception : know metastasis previously treat surgery stereotactic radiosurgery , AND Cerebral metastasis , still present , must stable least 90 day inclusion document two consecutive MRI scanner contrast medium , AND , asymptomatic Existence surgical medical condition , judgment Investigator , might interfere study . Patients willing comply provision protocol .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Melanoma</keyword>
	<keyword>Immunotherapy</keyword>
	<keyword>Dermatology</keyword>
	<keyword>cancer vaccine</keyword>
	<keyword>Plasmacytoid dendritic cell line</keyword>
	<keyword>Advanced Medicinal Therapy Product</keyword>
	<keyword>allogeneic</keyword>
</DOC>